NEW YORK (GenomeWeb) – Nuclea Biotechnologies Founder and former CEO Patrick Muraca is attempting to buy the bankrupt company's assets for $330,000 after they failed to sell at auction in January.

Don Beskrone, Nuclea's Chapter 7 trustee, filed a motion in US Bankruptcy Court for the District of Delaware on March 6 requesting that the court approve the sale of Nuclea's assets to NanoMolecularDx (NMDX), the company Muraca founded as a spinoff from Nuclea in 2015 upon being replaced as Nuclea's President and CEO by Donald Pogorzelski, a former president of Genzyme Diagnostics.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.